Pulmonary Arterial HypertensionPhase 2/3NCT00477269

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

A Phase 2/3 study testing Imatinib mesylate in people with Pulmonary Arterial Hypertension, run by Novartis Pharmaceuticals at 13 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Pulmonary Arterial Hypertension
What is being tested?: Imatinib mesylate
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 59 participants
Where: 13 sitesin 4 countries
Study dates: Apr 2006to Jan 2014
Phase: Phase 2/3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosis of PAH of either primary (idiopathic), familial or secondary to systemic sclerosis (excluding those with marked pulmonary fibrosis) according to World Conference on Pulmonary Hypertension classification (Venice, 2003).
Symptoms with a WHO class of II-IV

Who cannot join

Use of unspecific phosphodiesterase inhibitors (for example, pentoxyfillin, enoximon, milrinone or pimobendan) during the study
Chronic inhaled nitric oxide therapy from start to study completion
Treatment with catecholamines (for example, adrenalin, noradrenalin, dopamine),
Pre-existing lung diseases, including parasitic diseases affecting lungs, asthma, congenital abnormalities of the lungs, chest, and diaphragm.
Pulmonary artery or valve stenosis; pulmonary venous hypertension; chronic thromboembolic pulmonary hypertension
Acute heart failure or chronic left sided heart failure; congenital or acquired valvular or myocardial disease
Severe (systemic) arterial hypertension (> 200 mmHg (systolic) or > 120 mmHg (diastolic)) Other protocol-defined inclusion/exclusion criteria may apply

Trial locations and contacts

13 sites in 4 countries.

Country

City, postcode or hospital

13 sites in 4 countries

Germany4 sites

Novartis Investigative Site
Giessen, 35385
Novartis Investigative site
Giessen
Novartis Investigative Site
Hanover, Germany, 30625
Novartis Investigative site
Hanover

Other trials in Germany

United Kingdom4 sites

Novartis Investigative Site
Cambridge, Cambridgeshire, CB23 3RE
Novartis Investigative Site
Glasgow, G11 6NT
Novartis Investigative site
Glasgow
Novartis Investigative site
Papworth Everard

Other trials in United Kingdom

United States3 sites

Novartis Investigative Site
Los Angeles, California, 90073
Novartis Investigative Site
New York, New York, 10032
Novartis investigative site
Newark, New Jersey, 07112

Other trials in United States

Austria2 sites

Novartis Investigative Site
Graz, Austria, A-8036
Novartis Investigative site
Graz

Other trials in Austria

About this study

Official title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)

This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension
Being tested: Imatinib mesylate, Placebo
Keywords: Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571
Medical subject headings: Pulmonary Arterial Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Imatinib mesylateDrug
Also called Imatinib, Glivec, Gleevec, STI571, QTI571
PlaceboDrug

Study groups in NCT00477269
Study group	Role	What they receive
STI571	Experimental	STI571 Receives: Drug: Imatinib mesylate
Placebo	Placebo comparator	Placebo Receives: Drug: Placebo
All Patients	Experimental	Open label extension Receives: Drug: Imatinib mesylate

What is being measured

The primary outcome is the main question the study is designed to answer.

Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
Measured: 6 months
Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
Measured: 72 months
Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance <500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance >800 meters (with no rests) suggests mild or no limitation.
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient.
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Change From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded.
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)

Secondary outcomes (19)

Number of Patients With Pulmonary Hypertension (PAH) Assessd by World Health Organization (WHO) Classification on Physical Activity
PAH assessed according to the WHO classification: Class I Patients with PAH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion
Borg Score-Oxygen Saturation(SaO2) During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. The test was terminated if the patient became too distressed or if their SaO2% fell below 60%.
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Systolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Systolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Diastolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Diastolic blood pressure (mmHg) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Heart Rate (HR) During the Six Minutes Walk Test at Different Time Periods
Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Heart Rate (bpm) were recorded before the test at resting, at the end of the test and two minutes after the end of the test
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score During the Six Minutes Walk Test at Different Time Periods
Borg Score during Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. During the walk the patient was connected to a portable pulse oximeter via a finger probe. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Borg Score of Breathlessness was recorded using the following score of 0 to 10, how breathless do you feel? 0 is nothing at all and 10 is maximal breathlessness
Measured: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Mean Pulmonary Artery Pressure (PAP) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including right Pulmonary Arterial Pressure (PAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Measured: Baseline, and Study completion (Week 24)
Mean Pulmonary Artery Wedge Pressure (PAWP) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Arterial Wedge Pressure (PAWP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Measured: Baseline, and Study completion (Week 24)
Mean Systolic Arterial Pressure (SAP) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systolic Arterial Pressure (SAP). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Measured: Baseline, and Study completion (Week 24)
Mean Heart Rate (HR) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Heart Rate (HR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Measured: Baseline, and Study completion (Week 24)
Mean Cardiac Output (CO) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Cardiac Output (CO). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration.
Measured: Baseline, and Study completion (Week 24)
Mean Pulmonary Vascular Resistance (PVR) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. PVR calculated according to the equation:PVR = (PAP - PCWP)/CO
Measured: Baseline, and Study completion (Week 24)
Mean Systemic Vascular Resistance (SVR) at Baseline and Study Completion
The right heart catheter assessment was performed to assess several prognostic hemodynamic variables in pulmonary hypertension, including Systemic Vascular Resistance (SVR). Were assessed when the patient was in a stable hemodynamic rest state (as demonstrated by three consecutive Mean PAP and CO measurements within 10% of each other). PAP was assessed when the patient was breathing ambient air, every 2 minutes whilst breathing Nitric Oxide(NO) (1st and 2nd), 5 min after the end of NO administration, and 15 mins after the end of NO administration. SVR was calculated according to the equation: SVR = (Paorta - Pright atrium)/CO
Measured: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PaO2 at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaO2 levels at baseline and Study completion Week 24.
Measured: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PaCO2 at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PaCO2 levels at baseline and Study completion Week 24.
Measured: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PvO2 at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including PvO2 levels at baseline and Study completion Week 24.
Measured: Baseline, and Study completion (Week 24)
Blood Gas Measurement - Arterial Saturation at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Arterial Saturation levels at baseline and Study completion Week 24.
Measured: Baseline, and Study completion (Week 24)
Blood Gas Measurement - Venous Saturation at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including Venous Saturation levels at baseline and Study completion Week 24.
Measured: Baseline, and Study completion (Week 24)
Blood Gas Measurement - pH at Baseline and Study Completion
The right heart catheter assessment was performed to assess Blood Gas Measurements in pulmonary hypertension, including pH levels at baseline and Study completion Week 24. The pH scale measures how acidic or basic a substance is. It ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic.
Measured: Baseline, and Study completion (Week 24)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Apr 2006Jan 2014

First posted23 May 2007 (estimated)
Study startApr 2006
Primary completionJan 2014
Study completionJan 2014

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Pulmonary Arterial HypertensionStudies of the same condition, open and under way.
More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2/3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 59 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00477269
Sponsor's protocol ID: CSTI571E2203
Other IDs: 2005-005569-12, 2005
Status last verified: Mar 2015
First submitted: 22 May 2007
Last updated: 23 Mar 2015
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7. doi: 10.1164/rccm.201001-0123OC. Epub 2010 Jun 25.
PubMed 20581169

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH

All Pulmonary Arterial Hypertension trials

Study at a glance

From the registry record, last updated by the sponsor on 23 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)
ClinicalTrials.gov ID: NCT00477269
Acronym / sponsor ID: CSTI571E2203
Conditions: Pulmonary Arterial Hypertension
Keywords: Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571
Phase: Phase 2/3
Study type: Interventional
Recruitment status: Completed
Enrolment: 59 participants (actual)
Lead sponsor: Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
Study start: Apr 2006
Primary completion: Jan 2014 (actual)
Study completion: Jan 2014 (actual)
First posted: 23 May 2007 (estimated)
Results: Posted 23 Mar 2015

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 3

Arm	Type	Receives
STI571	Experimental	Drug: Imatinib mesylateSTI571
Placebo	Placebo comparator	Drug: PlaceboPlacebo
All Patients	Experimental	Drug: Imatinib mesylateOpen label extension

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

Diagnosis of PAH of either primary (idiopathic), familial or secondary to systemic sclerosis (excluding those with marked pulmonary fibrosis) according to World Conference on Pulmonary Hypertension classification (Venice, 2003).
Symptoms with a WHO class of II-IV

Key exclusion criteria (7 listed)

Use of unspecific phosphodiesterase inhibitors (for example, pentoxyfillin, enoximon, milrinone or pimobendan) during the study
Chronic inhaled nitric oxide therapy from start to study completion
Treatment with catecholamines (for example, adrenalin, noradrenalin, dopamine),
Pre-existing lung diseases, including parasitic diseases affecting lungs, asthma, congenital abnormalities of the lungs, chest, and diaphragm.
Pulmonary artery or valve stenosis; pulmonary venous hypertension; chronic thromboembolic pulmonary hypertension

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Imatinib mesylateAlso: Imatinib, Glivec, Gleevec, STI571, QTI571	Drug	All Patients, STI571
Placebo	Drug	Placebo

Primary outcome

Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core
Time frame: 6 months
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension
Time frame: 72 months
In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.
Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance <500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance >800 meters (with no rests) suggests mild or no limitation.
Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient.
Change From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded.

19 secondary outcomes

Number of Patients With Pulmonary Hypertension (PAH) Assessd by World Health Organization (WHO) Classification on Physical Activity
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion
Borg Score-Oxygen Saturation(SaO2) During the Six Minutes Walk Test at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Systolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Diastolic Blood Pressure During the Six Minutes Walk Test at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score-Heart Rate (HR) During the Six Minutes Walk Test at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Borg Score During the Six Minutes Walk Test at Different Time Periods
Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)
Mean Pulmonary Artery Pressure (PAP) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Mean Pulmonary Artery Wedge Pressure (PAWP) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Mean Systolic Arterial Pressure (SAP) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Mean Heart Rate (HR) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Mean Cardiac Output (CO) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Mean Pulmonary Vascular Resistance (PVR) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Mean Systemic Vascular Resistance (SVR) at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PaO2 at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PaCO2 at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - PvO2 at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - Arterial Saturation at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - Venous Saturation at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)
Blood Gas Measurement - pH at Baseline and Study Completion
Time frame: Baseline, and Study completion (Week 24)

Results and safety

Results posted to the registry on 23 Mar 2015, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
STI571	28	19
Placebo	31	23
All Patients	0	0

Primary outcome: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core

Time frame: 6 months. Number. Unit: participants

Measure	STI571 n = 28	Placebo n = 31
Paients with AE(s)	27	29
Death	3	3
SAE(s)	12	11

Population analysed: Safety Population all participants enrolled was included in this population

Primary outcome: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension

Time frame: 72 months. Number. Unit: participants

Measure	All Patients n = 22
Any AE(s)	22
Death	4
SAE(s)	16

Population analysed: No formal statistical analysis was performed in the extension phase of this study so no analysis data sets were defined. All summaries are based on all patients enrolled.

Primary outcome: Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods

Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24). Mean (Standard Deviation). Unit: meters

Measure	STI571 n = 28	Placebo n = 31
Day 32 (n=25,27)	10.2 (53.7)	8.2 (27.5)
week 8 (n=23,24)	17.0 (55.6)	15.5 (40.8)
week 12 (n=22,24)	21 (36.2)	7.8 (50.0)
week 16 (n=19, 23)	25.5 (43.1)	12.1 (47.9)
week 20 (n=19, 21)	38.3 (42.5)	12.8 (60.4)
study completion Week 24 (n=21, 12)	22.0 (63.1)	-1.0 (53.3)

Population analysed: The intention to treat population (ITT) will include all patients who received at least one dose of study medication.

Primary outcome: Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods

Time frame: Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24). Mean (Standard Deviation). Unit: number of stops

Measure	STI571 n = 28	Placebo n = 31
Day 32 (n=25,27)	-0.2 (0.7)	0.1 (0.4)
week 8 (n=23,24)	-0.2 (0.7)	0.0 (1.1)
week 12 (n=22,24)	-0.3 (0.9)	0.3 (0.9)
week 16 (n=19, 23)	-0.3 (0.8)	0.0 (0.2)
week 20 (n=19, 21)	-0.4 (1.0)	0.3 (1.0)
study completion Week 24 (n=21, 12)	-0.3 (0.8)	-0.1 (0.5)

Population analysed: The intention to treat population (ITT) will include all patients who received at least one dose of study medication.

19 secondary outcomes are reported in the full results.

Adverse events

Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Core - STI571	12 of 28 (42.9%)	26 of 28 (92.9%)	Not reported
Core - Placebo	11 of 31 (35.5%)	25 of 31 (80.6%)	Not reported
Extension - STI571	16 of 22 (72.7%)	21 of 22 (95.5%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2015.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 20581169Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7. doi: 10.1164/rccm.201001-0123OC. Epub 2010 Jun 25.

Related trials for Pulmonary Arterial Hypertension

Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Novartis Pharmaceuticals study director

Novartis Pharmaceuticals

Novartis principal investigator

Investigative site

13 sites in 4 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Imatinib mesylate in people with Pulmonary Arterial Hypertension, run by Novartis Pharmaceuticals at 13 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 13 sites in Germany, United Kingdom, United States, Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Mar 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core (time frame: 6 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00477269, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2015.